hydroxyethyl-ethylenediaminetrimethylenephosphonic acid | 1027202-77-2

• 分子结构分类: 有机化合物 - 有机酸及其衍生物
• 英文名称: hydroxyethyl-ethylenediaminetrimethylenephosphonic acid
• 英文别名: [1-[(1-Amino-4-hydroxybutan-2-yl)amino]-3-phosphonopropyl]phosphonic acid
• CAS: 1027202-77-2
• 化学式: C₇H₂₀N₂O₇P₂
• 分子量: 306.193
• InChiKey: GLTZITWXRVAILA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -9.1
• 重原子数：
  18
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  173
• 氢给体数：
  7
• 氢受体数：
  9

文献信息

• COMPOUND HAVING AFFINITY WITH CALCIFIED TISSUE
  申请人：NIHON MEDI-PHYSICS CO., LTD.

  公开号：EP1609797A1

  公开（公告）日：2005-12-28

  The present invention provides a compound excellent in accumulation on calcified tissues and ensuring rapid excretion into urine as well as rapid clearance from blood, useful as a diagnostic agent and a therapeutic agent, etc. The compound is a compound having affinity with a calcified tissue represented by the following formula: (AC)a-MC-(LI)b. In the formula, MC is a mother nucleus and represents a residue of a compound having a plurality of functional groups selected from the group consisting of an amino group, an amide group, a hydroxyl group, a thiol group, a thioether group, a sulfonyl group a phosphonyl group, an aldehyde group, a carboxyl group, a carbonyl group, a halogen, and a cyano group; AC is a group having affinity with a calcified tissue; LI is a ligand for binding to a metal atom; and a is an integer of 1 or more and b is 0 or an integer of 1 or more.

  本发明提供了一种在钙化组织上具有出色积累并确保快速从尿液中排出以及从血液中迅速清除的化合物，可用作诊断剂和治疗剂等。该化合物是与以下公式表示的钙化组织具有亲和力的化合物：(AC)a-MC-(LI)b。在该公式中，MC是母核，表示由多个功能基团中的一种或多种选择组成的残基化合物，该多个功能基团包括氨基、酰胺基、羟基、硫醇基、硫醚基、磺酰基、膦酸基、醛基、羧基、酰基、卤素和氰基；AC是具有钙化组织亲和力的基团；LI是与金属原子结合的配体；a是1或更多的整数，b是0或1或更多的整数。
• Bone marrow suppressing agents
  申请人：THE DOW CHEMICAL COMPANY

  公开号：EP0291605A2

  公开（公告）日：1988-11-23

  Bone marrow is suppressed by administering at least one bone marrow suppressing radionuclide composition having at least one of Samarium-153, Gadolinium-159, or Holmium-166 and at least one of ethylenediaminetetramethylenephosphonic acid, diethylenetriaminepentamethylenephosphonic acid, hydroxyethylethylenediaminetrimethylenephosphonic acid, nitrilotrimethylenephosphonic acid or tris(2-amino­ethyl)aminehexamethylenephosphonic acid, or a physiologically-acceptable salt thereof.

  通过施用至少一种具有钐-153、钆-159 或钬-166 中的至少一种和乙二胺四亚甲基膦酸中的至少一种的骨髓抑制放射性核素组合物来抑制骨髓、二乙烯三胺五亚甲基膦酸、羟乙基乙二胺三亚甲基膦酸、硝基三亚甲基膦酸或三(2-氨基乙基)胺六亚甲基膦酸或其生理上可接受的盐中的至少一种。
• Polypodal chelants for metallopharmaceuticals
  申请人：——

  公开号：US20020090342A1

  公开（公告）日：2002-07-11

  Tripodal polyaminophosphonate chelants are disclosed, as well as chelates of the chelants with metal ions to form radiopharmaceutical and radioactive, MRI and X-ray or CT imaging compounds and compositions. Therapeutic and imaging methods of use are also disclosed.

  公开了三足式聚氨基磷酸盐螯合剂，以及螯合剂与金属离子的螯合物，以形成放射性药物和放射性、核磁共振成像和 X 射线或 CT 成像化合物和组合物。还公开了治疗和成像使用方法。
• High dose radionuclide complexes for bone marrow suppression
  申请人：——

  公开号：US20020176818A1

  公开（公告）日：2002-11-28

  The present invention relates to a method of suppressing bone marrow (BM) and treating conditions that arise in or near bone such as cancer, myeloproliferative diseases, autoimmune diseases, infectious diseases, metabolic diseases or genetic diseases, with compositions having as their active ingredient a radionuclide complexed with a chelating agent such as macrocyclic aminophosphonic acid.

  本发明涉及一种抑制骨髓（BM）和治疗产生于骨骼或骨骼附近的疾病（如癌症、骨髓增生性疾病、自身免疫性疾病、传染性疾病、代谢性疾病或遗传性疾病）的方法，其组合物的有效成分是放射性核素与螯合剂（如大环胺膦酸）的络合物。
• Treatment of osteomyelitis with radiopharmaceuticals
  申请人：——

  公开号：US20030118508A1

  公开（公告）日：2003-06-26

  This invention relates to medical uses of radiopharmaceuticals. Specifically, the present invention relates to the use of radiopharmaceuticals to treat osteomyelitis. The present invention provides improved system and methods of for the direct delivery of radiopharmaceuticals to the site of osteomyelitis.

  本发明涉及放射性药物的医疗用途。具体而言，本发明涉及使用放射性药物治疗骨髓炎。本发明提供了将放射性药物直接输送到骨髓炎部位的改进系统和方法。